Lineage Cell Therapeutics Inc. (NYSEAMERICAN:LCTX) CEO Brian Culley and CFO Brandi Roberts present to investors at Proactive's One2One Virtual Investor Forum on October 14th, 2020. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities.
Proactive's One2One Virtual Investor Forum - Lineage Cell Therapeutics Inc
Quick facts: Lineage Cell Therapeutics
Price: 1.28 USD
Market Cap: $191.98 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lineage Cell Therapeutics named herein, including the promotion by the Company of Lineage Cell Therapeutics in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE